Clinical Trials Directory

Trials / Unknown

UnknownNCT01621919

Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1

Concentration of S-1 Metabolites in Tear and Plasma and Correlation With Its Side Effects in Patients Receiving S-1 Adjuvant Chemotherapy

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Seoul National University Bundang Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

S-1 has been also shown to be an effective drug for palliative chemotherapy in Eastern and Western GC patients. Recently, some case and small-sized studies have been reported on lacrimal drainage obstruction(LDO)caused by S-1.Suggested mechanism of LDO involves direct secretion of S-1 into the tear; thus the concentration of S-1 metabolite in tear is expected to be high in patients who developed LDO than in patients without LDO. We investigate the concentration of S-1 and its metabolites in tear and plasma and find out its correlation with side effects such as LDO. These results will also help us identify patients who are at high risk of developing S-1-associated side effects.

Detailed description

1. S-1 metabolites concentration in plasma 1. factors affecting plasma concentration * surgery subtype * serum creatinine 2. systemic adverse effects of S-1 and its correlation with plasma S-1 metabolites concentration * enteritis * fatigue 2. S-1 metabolites concentration in tears 1. correlation of tear concentration with plasma concentration 2. lacrimal drainage obstruction caused by S-1 administration, and its correlation with tear S-1 metabolites concentration 3. lacrimal drainage obstruction caused by S-1 administration, and its correlation with plasma S-1 metabolites concentration

Conditions

Timeline

Start date
2010-12-01
Primary completion
2012-12-01
Completion
2013-05-01
First posted
2012-06-18
Last updated
2012-06-18

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01621919. Inclusion in this directory is not an endorsement.